Implicity, a Paris, France-based leader in remote monitoring of cardiac implantable electronic devices, raised €4m in funding.
Backers included Serena, XAnge, Siparex and CapDecisif Management.
The company intends to use the funds to
– Respond to the exponential growth of the remote monitoring market for medical devices by strengthening the sales and marketing teams in France and throughout Europe.
– Explore new markets, with the deployment of the first data center in the United States in 2019.
– Accelerate the research and marketing of new “medical device” AI algorithms that improve the prognosis and follow-up of patients undergoing treatment while reducing the health resources required for this purpose.
Created in May 2016, Implicity offers an innovative platform for remote monitoring of patients implanted with cardiac implantable electronic devices (pacemakers, defibrillators). Created by Dr. Arnaud Rosier, cardiologist and AI researcher, this service allows remote management of alerts from connected devices from the five global manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic and Microport) via a single, cohesive platform.
After a year of deployment, the company is already the leader in France with more than 8,000 telemonitored patients daily.
Implicity had already raised €800k in October 2017 from Business Angels.